Definium Therapeutics, Inc. (DFTX)


Market Price (11/16/2026): $32.09 | Market Cap: $4.4 BilSector: Health Care | Industry: Biotechnology

Definium Therapeutics, Inc. (DFTX)


Market Price (11/16/2026): $32.09
Market Cap: $4.4 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -254 Mil

Stock price has recently run up significantly
12M Rtn12 month market price return is 137%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%

Key risks
DFTX key risks include [1] an overwhelming dependence on the successful clinical trial outcome and regulatory approval of its lead candidate, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23%
1 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.
2 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -254 Mil
4 Stock price has recently run up significantly
12M Rtn12 month market price return is 137%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
6 Key risks
DFTX key risks include [1] an overwhelming dependence on the successful clinical trial outcome and regulatory approval of its lead candidate, Show more.

DFTX in ETFs

Weight = DFTX's share of each fund

ITOT0.01%
IWM0.14%
IBB0.29%
IWO0.29%
NUSC0.25%
VTWO0.16%
SCHA0.11%
ESML0.09%
+4 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/13/2026

Nov 9: up 6.4% in one day (S&P 500 up 2.4%)
The stock gained on November 9 without company news to explain the rise, though the broader market also saw a relief rally that day.

Down 37.3% from its Jul 9 high to Nov 5, up 5.7% since (S&P 500 down 2.2%)
The run lower occurred largely without company-specific news to support the stock, with its largest declines on August 11 and November 2 occurring without company headlines.

Nov 10: down 2.1% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock declined after Definium reported its 2026Q2 results, which included zero revenue, a net loss of $-159M, and diluted EPS of $-1.44.

Show more
Prices as of 11/13/2026

Nov 9: up 6.4% in one day (S&P 500 up 2.4%)
The stock gained on November 9 without company news to explain the rise, though the broader market also saw a relief rally that day.

Down 37.3% from its Jul 9 high to Nov 5, up 5.7% since (S&P 500 down 2.2%)
The run lower occurred largely without company-specific news to support the stock, with its largest declines on August 11 and November 2 occurring without company headlines.

Nov 10: down 2.1% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock declined after Definium reported its 2026Q2 results, which included zero revenue, a net loss of $-159M, and diluted EPS of $-1.44.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -26.3% change in DFTX stock from 7/31/2026 to 11/15/2026 was primarily driven by a -20.0% change in the company's Shares Outstanding (Mil).
(LTM values as of)731202611152026Change
Stock Price ($)43.5232.08-26.3%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)109136-20.0%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/15/2026
ReturnCorrelation
DFTX-26.3% 
Market (SPY)1.2%34.9%
Sector (XLV)16.6%25.2%

Fundamental Drivers

The 46.6% change in DFTX stock from 4/30/2026 to 11/15/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)430202611152026Change
Stock Price ($)21.8832.0846.6%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)101136-25.7%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/15/2026
ReturnCorrelation
DFTX46.6% 
Market (SPY)5.5%18.5%
Sector (XLV)30.4%14.5%

Fundamental Drivers

null
null

Market Drivers

10/31/2025 to 11/15/2026
ReturnCorrelation
DFTX  
Market (SPY)11.8%19.6%
Sector (XLV)33.1%16.6%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/15/2026
ReturnCorrelation
DFTX  
Market (SPY)87.0%19.6%
Sector (XLV)59.4%16.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
DFTX Return-----137%137%
Peers Return-16%52%9%5%39%21%146%
S&P 500 Return27%-19%24%23%16%11%103%

Monthly Win Rates [3]
DFTX Win Rate-----55% 
Peers Win Rate56%64%53%50%58%45% 
S&P 500 Win Rate75%42%67%75%67%45% 

Max Drawdowns [4]
DFTX Max Drawdown------ 
Peers Max Drawdown-47%-36%-31%-30%-34%-35% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: AXSM, NBIX, ALKS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)

How Low Can It Go

DFTX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.8%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to AXSM, NBIX, ALKS

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

DFTX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to AXSM, NBIX, ALKS

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Definium Therapeutics, Inc. (DFTX)

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for a range of brain health disorders. The company's efforts are directed towards addressing conditions within psychiatry, addiction, pain management, and neurology.

Its product pipeline includes several key candidates. MM-120 is currently in Phase 2 clinical trials, being investigated for the treatment of generalized anxiety disorder, attention deficit hyperactivity disorder, and chronic pain. MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has completed Phase 1 trials for its potential application in treating opioid withdrawal. Additionally, the company is developing MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at alleviating the core symptoms of autism spectrum disorder.

MindMed's primary customers are patients suffering from these complex brain health conditions. The company's developments target the broad healthcare market, aiming to provide novel therapeutic solutions within the fields of mental health, addiction medicine, and neurology.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

```html

Robert Barrow Chief Executive Officer and Board Director

Robert Barrow was appointed Chief Executive Officer of Definium Therapeutics (formerly MindMed) in June 2021. Prior to his appointment as CEO, he served as the company's Chief Development Officer. Definium Therapeutics, under its former name MindMed, was initially a venture capital-backed company that went public in March 2020 via a reverse takeover on the Canadian NEO Exchange, and later uplisted to Nasdaq in April 2021.

Brandi Roberts, CPA Chief Financial Officer

Brandi Roberts serves as the Chief Financial Officer of Definium Therapeutics.

Daniel R. Karlin, MD, MA Chief Medical Officer

Daniel R. Karlin is the Chief Medical Officer of Definium Therapeutics. He joined the company in this role in connection with the acquisition of HealthMode, where he had served as CEO.

Stephanie Fagan, MS Chief Corporate Affairs Officer

Stephanie Fagan serves as the Chief Corporate Affairs Officer of Definium Therapeutics.

Mark Sullivan, JD Chief Legal Officer and Corporate Secretary

Mark Sullivan is the Chief Legal Officer and Corporate Secretary of Definium Therapeutics.

```

AI Analysis | Feedback

Definium Therapeutics, Inc. (DFTX) faces several key business risks inherent to its nature as a clinical-stage biopharmaceutical company focused on novel treatments for brain health disorders.

The most significant risk is the **risk of clinical trial failure and the uncertainty of regulatory approval** for its drug candidates. Definium Therapeutics is heavily invested in the success of its lead product candidates, DT120 (in Phase 3 for generalized anxiety disorder and major depressive disorder) and DT402 (in Phase 2a for autism spectrum disorder). Despite DT120 receiving FDA Breakthrough Therapy Designation for generalized anxiety disorder, there is no guarantee that these trials will be successful or that the company will secure the necessary regulatory approvals for commercialization. Failure at any stage of clinical development would severely impact the company's future prospects and financial viability.

A second key risk pertains to **regulatory and market acceptance challenges specific to psychedelic-inspired therapeutics**. Definium Therapeutics' approach involves applying scientific rigor to psychedelic-inspired compounds for psychiatric and neurological disorders. This nascent field may encounter unique regulatory hurdles, potentially leading to a longer or more complex approval process compared to traditional pharmaceuticals. Furthermore, even if approved, these novel treatments may face challenges in gaining widespread acceptance from the medical community, overcoming public perception biases, and securing favorable reimbursement policies from insurers.

Finally, the company faces **intellectual property risk**. As a biopharmaceutical company developing novel compounds, Definium Therapeutics' long-term value and competitive position are highly dependent on its ability to obtain, maintain, and defend robust patent protection for its drug candidates and proprietary technologies. Any challenges to its intellectual property, or an inability to secure strong patent portfolios, could undermine its market exclusivity and expose it to competition.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable markets for Mind Medicine (MindMed) Inc.'s main products are as follows:

  • MM-120 for Generalized Anxiety Disorder (GAD):
    • The global generalized anxiety disorder treatment market was valued at approximately USD 11.93 billion in 2024 and is predicted to grow to around USD 17.32 billion by 2034.
    • Another estimate places the global market at USD 2.14 billion in 2025, expected to reach USD 5.06 billion by 2035.
    • In 2023, the Generalized Anxiety Disorder market size in the 7 Major Markets (7MM, which includes the United States, EU4, and the United Kingdom, and Japan) reached approximately USD 1,560 million.
    • The United States market for GAD treatment was nearly USD 1,019 million in 2023, representing nearly 65% of the 7MM market.
  • MM-120 for Attention Deficit Hyperactivity Disorder (ADHD):
    • The global attention deficit hyperactivity disorder (ADHD) therapeutics market size is estimated at US$ 25.05 billion in 2024 and is forecasted to reach US$ 45.51 billion by 2034.
    • Another report indicates the ADHD market reached USD 9.6 billion in 2023 and is expected to reach USD 13.6 billion by 2034.
    • The ADHD therapeutics market value across eight major markets (the US, the UK, France, Germany, Spain, Italy, Japan, and Canada) was projected to rise from $6.9 billion in 2013 to $9.9 billion by 2020.
    • North America is expected to contribute 40% of the market's growth for ADHD drugs.
  • MM-120 for Chronic Pain:
    • The global chronic pain treatment market was valued at USD 78.0 billion in 2024, projected to reach USD 83.4 billion in 2025 and USD 155.2 billion by 2035.
    • Another source valued the global chronic pain treatment market at USD 90.72 billion in 2024 and anticipates it will reach USD 152.42 billion by 2032.
    • North America accounted for the largest market share at 45% in 2024, with over USD 40 billion in chronic pain treatment utilization.
    • North America is forecasted to hold the largest market share at 40.8% in 2025.
  • MM-110 for Opioid Withdrawal:
    • The global Opioid Withdrawal Treatment Market is estimated to be valued at USD 1.91 billion in 2026, and projected to reach USD 4.33 billion by 2035.
    • The opioid addiction treatment market will be worth $2.4 billion in eight major world markets by 2033.
    • The market size for opioid withdrawal syndrome in the 7MM (United States, EU4, and the United Kingdom, and Japan) reached approximately USD 1.3 billion in 2022.
    • The United States market for opioid withdrawal treatment was projected at USD 0.61 billion in 2025.
    • North America leads the global opioid withdrawal treatment market with approximately 50% share.
  • MM-402 for Autism Spectrum Disorder (ASD):
    • The global autism spectrum disorder treatment market size was estimated at USD 2.16 billion in 2024 and is projected to reach USD 3.95 billion by 2033.
    • Another source indicates the global autism spectrum disorder treatment market was valued at USD 2.35 billion in 2024 and is predicted to increase to approximately USD 4.22 billion by 2034.
    • North America held the largest share of 42.73% of the global market in 2024.
    • The U.S. autism spectrum disorder treatment market size was exhibited at USD 1.00 billion in 2024 and is projected to be worth around USD 1.84 billion by 2034.

AI Analysis | Feedback

Definium Therapeutics, Inc. (DFTX) has several key drivers expected to fuel its future revenue growth over the next 2-3 years, primarily centered around the advancement and potential commercialization of its pipeline of novel therapeutics for brain health disorders.

  1. Successful Commercialization of DT120 for Generalized Anxiety Disorder (GAD): The most significant driver is the potential approval and launch of DT120 (formerly MM-120), an orally disintegrating tablet formulation, for Generalized Anxiety Disorder. This lead product candidate is currently in Phase 3 clinical trials, with topline data from the Voyage study anticipated in the first half of 2026 and the Panorama study in the second half of 2026. DT120 has received FDA Breakthrough Therapy Designation for GAD, which could expedite its development and regulatory review process. Analysts project substantial peak U.S. sales for MM120, with potential revenue reaching $2.29 billion by 2031 in the multi-billion-dollar GAD market.
  2. Expansion of DT120 into Major Depressive Disorder (MDD): Beyond GAD, DT120 is also being evaluated in Phase 3 trials for Major Depressive Disorder, representing a significant additional market opportunity. A successful outcome in these trials and subsequent regulatory approval would considerably broaden the potential patient population and revenue stream for DT120.
  3. Advancement of DT402 for Autism Spectrum Disorder (ASD): The company's pipeline includes DT402 (formerly MM-402), an R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in Phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. Positive clinical trial results and progression to later stages of development could open up another significant revenue pathway in a distinct therapeutic area.
  4. Progression of MM-110 for Opioid Withdrawal: The company is also developing MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, which has completed Phase 1 for the treatment of opioid withdrawal. Successful further development and potential commercialization of MM-110 would address another critical area of unmet medical need and contribute to revenue growth.
  5. Strategic Preparedness for Commercial Launch: Definium Therapeutics is actively advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. This proactive approach to market entry and infrastructure development is crucial for maximizing revenue generation upon product approval.

AI Analysis | Feedback

Share Repurchases

No significant share repurchases were identified for Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) within the last 3-5 years.

Share Issuance

  • The company completed a public offering in November 2025, raising approximately $259 million, with net proceeds of $242.8 million.
  • In March 2024, Definium Therapeutics (then Mind Medicine) entered into private placement agreements for 12,500,000 common shares at $6 per share, generating gross proceeds of $75 million.
  • Shares outstanding significantly increased from 27 million in fiscal year 2021 to 89 million in fiscal year 2025.

Inbound Investments

  • Definium Therapeutics (formerly Mind Medicine) received approximately $259 million through a public offering in November 2025.
  • In March 2024, the company secured $75 million in funding from Deep Track Capital, LP, and Commodore Capital through a private placement.
  • MindMed has raised funding over nine rounds since November 2019, including post-IPO rounds in March 2021 and August 2023.

Outbound Investments

MindMed acquired HealthMode in October 2020.

Capital Expenditures

  • Research and development (R&D) expenditures represent the primary focus of capital deployment, with annual R&D expenses increasing from $34.79 million in FY 2021 to $117.67 million in FY 2025.
  • The company invested $31.0 million in research and development during Q3 2025.
  • Traditional capital expenditures (property, plant, and equipment) have been reported as minimal or not applicable.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

DFTXAXSMNBIXALKSMedian
NameDefinium.Axsome T.Neurocri.Alkermes  
Mkt Price32.09142.12167.3547.0294.57
Mkt Cap4.47.517.07.97.7
Rev LTM08653,7021,7541,309
Op Inc LTM-254-16391091-36
FCF LTM-191-831,03722772
FCF 3Y Avg-127-106690344119
CFO LTM-191-821,06624381
CFO 3Y Avg-127-105726380137

Growth & Margins

DFTXAXSMNBIXALKSMedian
NameDefinium.Axsome T.Neurocri.Alkermes  
Rev Chg LTM-54.2%38.0%15.3%38.0%
Rev Chg 3Y Avg-57.2%27.8%3.7%27.8%
Rev Chg Q-51.9%41.2%21.8%41.2%
QoQ Delta Rev Chg LTM-11.4%9.7%5.2%9.7%
Op Inc Chg LTM-68.1%16.1%64.4%-74.6%-26.0%
Op Inc Chg 3Y Avg-46.3%1.0%42.5%-31.4%-15.2%
Op Mgn LTM--18.9%24.6%5.2%5.2%
Op Mgn 3Y Avg--42.1%23.8%16.5%16.5%
QoQ Delta Op Mgn LTM-4.7%0.7%-3.4%0.7%
CFO/Rev LTM--9.5%28.8%13.9%13.9%
CFO/Rev 3Y Avg--22.2%24.6%24.4%24.4%
FCF/Rev LTM--9.5%28.0%13.0%13.0%
FCF/Rev 3Y Avg--22.3%23.3%22.1%22.1%

Valuation

DFTXAXSMNBIXALKSMedian
NameDefinium.Axsome T.Neurocri.Alkermes  
Mkt Cap4.47.517.07.97.7
P/S-8.64.64.54.6
P/Op Inc-17.2-45.618.786.60.8
P/EBIT-13.1-49.421.180.64.0
P/E-12.9-47.424.2-22,488.2-30.2
P/CFO-22.8-91.116.032.5-3.4
Total Yield-7.7%-2.1%4.1%-0.0%-1.1%
Dividend Yield0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg--1.9%5.1%6.7%5.1%
D/E0.00.00.00.20.0
Net D/E-0.2-0.0-0.00.1-0.0

Returns

DFTXAXSMNBIXALKSMedian
NameDefinium.Axsome T.Neurocri.Alkermes  
1M Rtn-0.0%-9.6%23.3%14.1%7.0%
3M Rtn-24.7%-33.5%9.6%-4.2%-14.4%
6M Rtn52.9%-37.6%5.6%25.5%15.5%
12M Rtn137.5%1.7%15.5%61.9%38.7%
3Y Rtn137.5%138.0%53.9%101.2%119.4%
1M Excs Rtn-4.7%-10.5%23.8%18.9%7.1%
3M Excs Rtn-27.5%-32.7%9.9%-4.1%-15.8%
6M Excs Rtn50.0%-40.4%2.8%22.6%12.7%
12M Excs Rtn126.3%-10.4%2.7%38.5%20.6%
3Y Excs Rtn63.7%56.8%-28.8%30.3%43.5%

Comparison Analyses

null

Financials

Segment Financials

Operating Income by Segment
$ Mil202520242023
Research and development of the Company’s neurological drug development platform-166-104-94
Total-166-104-94


Net Income by Segment
$ Mil202520242023
Research and development of the Company’s neurological drug development platform-184-109-96
Total-184-109-96


Assets by Segment
$ Mil2023202220212020
Research and development of the Company’s neurological drug development platform12517016482
Total12517016482


Price Behavior

Price Behavior
Market Price$32.08 
Market Cap ($ Bil)4.4 
First Trading Date11/15/2016 
Distance from 52W High-33.8% 
   50 Days200 Days
DMA Price$36.07$30.43
DMA Trenddown 
Distance from DMA-11.1%5.4%
 3M1YR
Volatility60.0%81.2%
Downside Capture316.45 
Upside Capture204.18 
Correlation (S&P 500)40.6% 
DFTX Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta2.201.591.200.980.27-0.09
Up Beta-2.52-0.89-0.860.46-0.80-0.07
Down Beta0.291.190.641.580.340.58
Up Capture318%195%145%185%160%14%
Bmk +ve Days12182862130427
Stock +ve Days9202963109109
Down Capture304%215%228%43%25%15%
Bmk -ve Days10253664121325
Stock -ve Days132334629696

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with DFTX
DFTX138.3%81.2%1.55-
Sector ETF (XLV)25.8%16.8%1.1816.6%
Equity (SPY)11.6%13.7%0.5419.6%
Gold (GLD)-7.9%28.9%-0.296.2%
Commodities (DBC)33.8%21.3%1.26-13.2%
Real Estate (VNQ)10.7%14.2%0.4711.2%
Bitcoin (BTCUSD)-33.0%43.7%-0.7911.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with DFTX
DFTX18.9%81.2%1.55-
Sector ETF (XLV)9.1%15.4%0.3916.6%
Equity (SPY)11.5%17.3%0.4919.6%
Gold (GLD)15.9%19.2%0.666.2%
Commodities (DBC)7.8%19.6%0.28-13.2%
Real Estate (VNQ)1.3%18.9%-0.0411.2%
Bitcoin (BTCUSD)2.2%51.6%0.2311.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with DFTX
DFTX9.0%81.2%1.55-
Sector ETF (XLV)13.0%16.8%0.6416.6%
Equity (SPY)15.5%18.0%0.7319.6%
Gold (GLD)11.1%16.6%0.546.2%
Commodities (DBC)7.6%18.1%0.33-13.2%
Real Estate (VNQ)6.3%20.7%0.2611.2%
Bitcoin (BTCUSD)58.4%66.2%0.9811.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity9.6 Mil
Short Interest: % Change Since 10152026-4.3%
Average Daily Volume1.7 Mil
Days-to-Cover Short Interest5.8 days
Basic Shares Quantity135.9 Mil
Short % of Basic Shares7.1%

Earnings Returns History

Updated 11/12/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/9/2026-2.1%  
8/6/20260.0%-4.9%-17.4%
5/7/2026-5.0%-8.0%-0.8%
2/26/20260.9%1.5%3.4%
SUMMARY STATS   
# Positive211
# Negative222
Median Positive0.5%1.5%3.4%
Median Negative-3.5%-6.4%-9.1%
Max Positive0.9%1.5%3.4%
Max Negative-5.0%-8.0%-17.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/9/2026-2.1%  
8/6/20260.0%-4.9%-17.4%
5/7/2026-5.0%-8.0%-0.8%
2/26/20260.9%1.5%3.4%
SUMMARY STATS   
# Positive211
# Negative222
Median Positive0.5%1.5%3.4%
Median Negative-3.5%-6.4%-9.1%
Max Positive0.9%1.5%3.4%
Max Negative-5.0%-8.0%-17.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/09/202610-Q
06/30/202608/06/202610-Q
03/31/202605/07/202610-Q
12/31/202502/26/202610-K
09/30/202511/06/202510-Q
06/30/202507/31/202510-Q
03/31/202505/08/202510-Q
12/31/202403/06/202510-K
09/30/202411/07/202410-Q
06/30/202408/13/202410-Q
03/31/202405/08/202410-Q
12/31/202302/28/202410-K
09/30/202311/02/202310-Q
06/30/202308/03/202310-Q
03/31/202305/04/202310-Q
12/31/202203/09/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/09/202610-Q
06/30/202608/06/202610-Q
03/31/202605/07/202610-Q
12/31/202502/26/202610-K
09/30/202511/06/202510-Q
06/30/202507/31/202510-Q
03/31/202505/08/202510-Q
12/31/202403/06/202510-K
09/30/202411/07/202410-Q
06/30/202408/13/202410-Q
03/31/202405/08/202410-Q
12/31/202302/28/202410-K
09/30/202311/02/202310-Q
06/30/202308/03/202310-Q
03/31/202305/04/202310-Q
12/31/202203/09/202310-K
09/30/202211/10/202210-Q
06/30/202208/11/202210-Q
03/31/202205/16/202210-Q
12/31/202103/28/202210-K
09/30/202111/12/20216-K
06/30/202108/13/20216-K
03/31/202105/14/20216-K

Insider Activity

Updated 9/29/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Karlin, DanielChief Medical OfficerDirectSell929202636.5710,853396,89428,994,378Form
2Barrow, RobertChief Executive OfficerDirectSell929202636.5731,5501,153,78480,932,701Form
3Wiley, Matthew TChief Commercial OfficerDirectSell929202636.573,097113,25713,129,947Form
4Sullivan, MarkChief Legal OfficerDirectSell929202636.5714,051513,84518,073,918Form
5Roberts, BrandiChief Financial OfficerDirectSell929202636.573,377123,49714,427,889Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Karlin, DanielChief Medical OfficerDirectSell929202636.5710,853396,89428,994,378Form
2Barrow, RobertChief Executive OfficerDirectSell929202636.5731,5501,153,78480,932,701Form
3Wiley, Matthew TChief Commercial OfficerDirectSell929202636.573,097113,25713,129,947Form
4Sullivan, MarkChief Legal OfficerDirectSell929202636.5714,051513,84518,073,918Form
5Roberts, BrandiChief Financial OfficerDirectSell929202636.573,377123,49714,427,889Form
6Barrow, RobertChief Executive OfficerDirectSell904202637.9419,023721,73356,706,642Form
7Sullivan, MarkChief Legal OfficerDirectSell626202645.0313,008585,75014,435,312Form
8Roberts, BrandiChief Financial OfficerDirectSell626202645.033,013135,6759,433,200Form
9Barrow, RobertChief Executive OfficerDirectSell626202645.0329,2081,315,23649,454,017Form
10Karlin, DanielChief Medical OfficerDirectSell626202645.0310,035451,87622,662,788Form
11Wiley, Matthew TChief Commercial OfficerDirectSell626202645.032,867129,1017,863,724Form
12Karlin, DanielChief Medical OfficerDirectSell326202618.478,018148,0927,633,965Form
13Sullivan, MarkChief Legal OfficerDirectSell326202618.4710,702197,6665,006,829Form
14Barrow, RobertChief Executive OfficerDirectSell326202618.4724,431451,24113,897,825Form
15Karlin, DanielChief Medical OfficerDirectSell1229202513.155,60073,6235,587,761Form
16Barrow, RobertChief Executive OfficerDirectSell1229202513.1525,791339,07210,234,559Form
17Sullivan, MarkChief Legal OfficerDirectSell1229202513.1511,276148,2443,714,998Form
18Sullivan, MarkChief Legal OfficerDirectSell92620259.7711,278110,1862,870,934Form
19Barrow, RobertChief Executive OfficerDirectSell92620259.7725,797252,0377,857,698Form
20Karlin, DanielChief Medical OfficerDirectSell92620259.777,70475,2684,207,206Form

Investor Activity (13F)

Updated Nov 16, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Trails Edge Capital Partners, LP$32.9 Mil7.7%26New13F
Octagon Capital Advisors LP$46.1 Mil5.1%29New13F
Catalio Capital Management, LP$19.6 Mil4.1%41New13F
Commodore Capital LP$37.8 Mil2.2%36New13F
Patient Square Capital LP$6.3 Mil1.1%29New13F
Tri Locum Partners LP$7.0 Mil1.0%17New13F
Avoro Capital Advisors LLC$94.5 Mil0.9%30New13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Avoro Capital Advisors LLC$94.5 Mil0.9%30New13F
Octagon Capital Advisors LP$46.1 Mil5.1%29New13F
Commodore Capital LP$37.8 Mil2.2%36New13F
Trails Edge Capital Partners, LP$32.9 Mil7.7%26New13F
Catalio Capital Management, LP$19.6 Mil4.1%41New13F
Tri Locum Partners LP$7.0 Mil1.0%17New13F
Patient Square Capital LP$6.3 Mil1.1%29New13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Avoro Capital Advisors LLC$94.5 Mil0.9%30New13F
Octagon Capital Advisors LP$46.1 Mil5.1%29New13F
Commodore Capital LP$37.8 Mil2.2%36New13F
Trails Edge Capital Partners, LP$32.9 Mil7.7%26New13F
Catalio Capital Management, LP$19.6 Mil4.1%41New13F
Tri Locum Partners LP$7.0 Mil1.0%17New13F
Patient Square Capital LP$6.3 Mil1.1%29New13F
Core Cache Last Updated: 11/15/2026